Lucinactant
As of the edition of 20 October 2026, Lucinactant is a drug: marketed, first approved in 2012 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Unknown
- Brand name
- Surfaxin
- First approved
- 6 March 2012 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Lees Pharmaceutical Hk
- Registered trials
- 8, 5 stopped early
- Disease areas
- Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Infections
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 7 | 3 | 0 | 4 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lees Pharmaceutical Hk | Acquired holder | 2024 to now |